



## US clinical trial results provisionally accepted by leading medical journal; abstract shows significant outcomes from treatment with Mente Autism

**Perth, Australia & Malta – 25 June 2018** – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions improving the lives of children with autism, is pleased to announce that the abstract of the US clinical trial results has been published by *Frontiers in Neurology*, one of the world’s leading and most cited medical journals.

*Frontiers in Neurology* has advised that it has provisionally accepted the clinical trial article, “*The Treatment of Autism Spectrum Disorder with Auditory Neurofeedback: A Randomized Placebo Controlled Trial Using the MENTE Autism Device*”, for publication.

While the full article is not yet available, it is expected to be published soon and a full copy of the abstract is available online at: [www.frontiersin.org/articles/10.3389/fneur.2018.00537/abstract](http://www.frontiersin.org/articles/10.3389/fneur.2018.00537/abstract)

The abstract states:

**“Our results show that a short 12 week course of NFB [neurofeedback] using the Mente Autism device can lead to significant changes in brain activity (qEEG), sensorimotor behaviour (posturography), and behaviour (standardized questionnaires) in ASD children... Similar changes were not detected in the Control group.”** (Carrick et al. 2018<sup>1</sup>)

Neurotech Founder and Non-Executive Director Dr Adrian Attard Trevisan stated: “*Even though we have only been provided with an abstract, the results of the trial show that using our readily accessible, home-based Mente Autism treatment can have a wide ranging and beneficial impact on children with autism spectrum disorder (“ASD”, or “autism”), across the modulation of brainwaves, behaviours and even balance. The fact that changes were observed across all three areas, and not in the control group, is significant in its own right and the best outcome we could have hoped for. This is an outstanding outcome that supports our view that Mente can bring substantial change to the management of ASD.*”

The Company notes that the Carrick Institute chose *Frontiers of Neurology* for publication of the results – this journal is considered one of the most respected and often cited scientific journals for neurology (see below table). The calibre of the study and extent of international collaboration is evident in the preparation of the article for publication, involving academic authors from institutions such as the Carrick Institute, the University of Cambridge, the Harvard Macy Institute, the University of Wyoming, the Dubai Medical College, as well as government and private sector organisations such as the Leeds and York Partnership NHS Foundation Trust (UK), the Dubai Health Authority and Plasticity Brain Centers (US).

Wolfgang Storf, CEO of Neurotech International said: “*This has been a long journey for the Company, its shareholders and distributors, and while we’re not quite at the finish line with the full publication to come, the results noted in the abstract are very exciting for us. This continues to validate all the effort that the team has put into the science behind Mente Autism and confirms the positive preliminary findings made at Cambridge in September last year. It is important to remember that this publication remains an independent process administered by the Carrick Institute and now Frontiers, and therefore we don’t have control over the timing of the full publication of the results. We are looking forward to seeing all of the detail when it is made available.*”

---

<sup>1</sup> Carrick F, Pagnacco G, Hankir A, Abdulrahman M, Zaman R, Kalambaheti E, Barton D, Link P and Oggero E. The Treatment of Auditory Spectrum Disorder with Neurofeedback: A Randomized Placebo Controlled Trial Using the MENTE Autism Device. *Frontiers of Neurology*. Provisionally accepted as at June 2018. doi: 10.3389/fneur.2018.00537

## *Top 10 most cited open-access journals in Clinical Neurology*




Figure 1. Total number of citations in 2016 to articles published in 2014 and 2015, for the top 10 most cited open-access journals in Clinical Neurology. Bar plot shows Frontiers in Neurology (in red) ranks 2nd most cited over 13 open-access journals indexed. The results are based on the 2016 Journal Citation Reports, released in 2017 by Clarivate Analytics.

*Source: Frontiers journal ranking analysis: Clinical Neurology (June 2017, Impact Analysis).*

### US CLINICAL TRIAL

The US Clinical Trial was a double blinded, independent clinical trial to assess the efficacy of the Mente Autism device, administered by the Carrick Institute.

Subjects were randomised to an active group receiving neurofeedback using the Mente device and a control group using a sham device. Both groups used the device each morning for 45 minutes over a 12 week home based trial without any other clinical interventions. Pre and post standard ASD [autism] questionnaires, qEEG and posturography were used to measure the effectiveness of the treatment`.

Data collection for the US clinical trial was completed in January 2018, and as noted on Frontiers of Neurology’s website, was submitted for review in February 2018. As a fully independent study, Neurotech has had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

-ends-

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with autism spectrum disorder. Designed for home use, it helps relax the minds of children on the spectrum which in turn helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries:

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420